Skip to main content.

Nausheen Ahmed, M.D.

Nausheen Ahmed portrait
Associate Professor, Hematologic Malignancies and Cellular Therapeutics
nahmed5@kumc.edu

Professional Background

I am a board certified hematologist and graduated from hematology oncology fellowship at Tufts University in 2015. Since then I completed an advanced fellowship training in stem cell transplant and immune effector cell therapy at Case Western. My passion is treating patients with hematologic disorders such as leukemia, lymphoma and myeloma with emphasis on stem cell transplantation and immune effector cell therapies.
I have expertise in managing transplant and cellular therapy related toxicities. I also focus on late effects and survivorship in our patient population. I am a compassionate and caring advocate for my patients.

I serve as a site PI and sub-PI for several pivotal clinical trials in the field of transplantation and immune effector cell therapy at the University of Kansas Cancer Center.

Education and Training
  • MBBS, Internal Medicine, Aga Khan University Medical College, Karachi, Pakistan
  • Clinical Fellowship, Hematology and Medical Oncology, Tufts University School of Medicine at Baystate Health System, Boston, MA
  • Clinical Fellowship, Bone Marrow Transplant & Cellular Therapy, Case Western Reserve University at University Hospitals Seidman Cancer Center, Cleveland, Ohio

Research

Overview

I am a clinical researcher, and my research focus revolves around cellular therapies as well as access and disparities to clinical trials and standard-of-care cellular therapies. My research and scholarly activities are an integral part of my commitment to advancing the field of cellular therapies and improving patient outcomes. Over the years, I have been involved in a range of research activities, including retrospective institutional and multi-institutional research, collaborating with colleagues across the globe on Center for International Blood and Marrow Transplant Registry (CIBMTR) proposals, participating as an American Society of Transplant and Cellular Therapy (ASTCT) survivorship steering committee member ( an international transplant and cellular therapy society), and participating in several ASTCT and CIBMTR working committees. I am also committed to outreach and clinical trial enrollment efforts, working to ensure that underserved populations have access to the latest treatments and therapies. As a principal investigator (PI) on cooperative group trials and subsite investigator-initiated trials (IITs), I have been able to contribute to the development of new treatment options and improve our understanding of the underlying mechanisms of disease.